NuCana Reports Third Quarter 2026 Financial Results and Provides Business Update
Development Programme for NUC-7738 Advances with Three Presentations Planned at ESMO Immuno-Oncology
Development Programme for NUC-7738 Advances with Three Presentations Planned at ESMO Immuno-Oncology